Department of Obstetrics and Gynaecology, Landeskrankenhaus Bregenz, Bregenz, Austria.
Curr Opin Obstet Gynecol. 2009 Nov;21 Suppl 1:S1-9. doi: 10.1097/01.gco.0000361658.98177.59.
Approximately 12 million women worldwide use the levonorgestrel-releasing intrauterine system (IUS), with approximately 180,000 users of this IUS currently reported in Austria. A patient satisfaction study of 591 women in Austria revealed a high number of 'very satisfied' (79%) and 'satisfied' (19%) patients. Reliability, comfort, excellent compatibility and less severe, shorter and less painful monthly periods were the most frequently named advantages of the levonorgestrel-releasing IUS. Medication-induced cervical priming before insertion can be carried out on a routine or selective basis (for example in nullipara, in women who have undergone cervical conisation or in women who have previously experienced painful insertion). There is, at present, no evidence of an increased rate of breast cancer through use of the levonorgestrel-releasing IUS. A directly comparative study with oral contraceptives in young nullipara showed excellent results for the levonorgestrel-releasing IUS, with no perforations, inflammation or pregnancies.
全球约有 1200 万女性使用左炔诺孕酮宫内节育系统（IUS），目前奥地利约有 18 万名该 IUS 用户。一项对奥地利 591 名女性的患者满意度研究显示，有大量“非常满意”（79%）和“满意”（19%）的患者。可靠性、舒适性、极好的兼容性以及经量减少、经期缩短和减轻疼痛是左炔诺孕酮 IUS 最常被提及的优势。在插入前，可根据需要对子宫颈进行药物预处理（例如，在初产妇、接受过宫颈锥切术的女性或以前经历过插入疼痛的女性中）。目前，没有证据表明使用左炔诺孕酮 IUS 会增加乳腺癌的发病率。一项针对年轻初产妇的与口服避孕药的直接比较研究显示，左炔诺孕酮 IUS 效果极佳，无穿孔、炎症或妊娠。
